Document Detail

Feasibility and short-term efficacy of percutaneous mitral annular reduction for the therapy of functional mitral regurgitation in patients with heart failure.
MedLine Citation:
PMID:  16817176     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: While functional mitral regurgitation (MR) commonly accompanies heart failure and contributes to heart failure progression, mitral repair in the setting of HF is not routinely practiced because of the attendant significant morbidity and mortality. This limitation has fostered the development of percutaneous devices to reduce MR, and our group has recently reported the short- and long-term effectiveness of a percutaneous mitral annuloplasty device placed in the coronary sinus (Percutaneous Mitral Annuloplasty Device (PMAD), Cardiac Dimensions(R), Inc., Kirkland, WA) in reducing MR in experimental animal models of heart failure with associated MR. In this article, we report results of a "first-in-human" study of temporary placement of the PMAD device. The aim of this study was to demonstrate the feasibility and safety of temporary deployment of this device in patients with functional MR in association with heart failure. METHODS: Five patients undergoing scheduled coronary angiography with heart failure and functional MR (mean age 52 +/- 9 [SD] years) were recruited, and four had anatomy suitable for deployment of the device. Transthoracic echocardiography and coronary angiography were performed before and after temporary placement and tensioning of the PMAD via the right internal jugular vein. RESULTS: Temporary deployment of the device resulted in a significant reduction in the septal-lateral mitral annular dimension from 35.5 +/- 4.7 to 32.2 +/- 4.6 mm (P = 0.02), with evidence of a reduction in the MR color Doppler area from 98.3 +/- 43.6 to 83.3 +/- 35.1 mm(2) (P = 0.09). There were no complications. CONCLUSIONS: This first-in-human study of a novel device for percutaneous treatment of functional MR has shown that temporary placement of this device in the coronary sinus/great cardiac vein of patients with heart failure and MR is feasible and safe. Evidence of temporary reduction in MR and a reduction in mitral annular area indicate promise for device effectiveness in chronic implantation.
Stephen J Duffy; Jacob Federman; Catherine Farrington; David G Reuter; Meroula Richardson; David M Kaye
Related Documents :
9382006 - Short atrioventricular delay reduces the degree of mitral regurgitation in patients wit...
17600766 - Ischemic mitral regurgitation: mechanisms and echocardiographic classification.
305766 - Posterior ventricular aneurysm, severe mitral regurgitation, and rupture of the left ve...
6221796 - Cor triatriatum in an adult with mitral regurgitation and massive left atrial enlargement.
17722036 - The ast petal dedicated bifurcation stent: first-in-human experience.
23040596 - Development of a method to risk stratify patients with heart failure for 30-day readmis...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions     Volume:  68     ISSN:  1522-1946     ISO Abbreviation:  Catheter Cardiovasc Interv     Publication Date:  2006 Aug 
Date Detail:
Created Date:  2006-08-28     Completed Date:  2007-01-19     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  100884139     Medline TA:  Catheter Cardiovasc Interv     Country:  United States    
Other Details:
Languages:  eng     Pagination:  205-10     Citation Subset:  IM    
The Alfred and Baker Medical Unit, Baker Heart Research Institute, Melbourne, Victoria, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Feasibility Studies
Heart Failure / complications*
Middle Aged
Mitral Valve / pathology,  surgery*
Mitral Valve Insufficiency / epidemiology,  etiology,  pathology,  therapy*
Pilot Projects
Prostheses and Implants*

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  First report of prevalence of non-syndromic hereditary prosopagnosia (HPA).
Next Document:  Early administration of abciximab bolus in the emergency department improves angiographic outcome af...